Use of heat shock protein 70 preparations in vaccination against cancer and infectious disease

Abstract

The use of cognate heat shock protein 70-peptide complex to elicit an immune response against cancer and viral, bacterial and other infectious agents.

We claim:  
     
         1 . An immunogenic composition comprising a heat shock protein 70-peptide complex wherein the complex is obtained from tumor cells or cells infected with a virus, bacteria or other infectious agent.  
     
     
         2 . An immunogenic composition according to  claim 1  wherein the complex is obtained from cells from a tumor cell line or from a cell line infected with a virus, bacteria or other infectious agent.  
     
     
         3 . An immunogenic composition according to  claim 1  wherein the complex is obtained from bacteria-infected cells.  
     
     
         4 . An immunogenic composition according to  claim 3  wherein the complex is obtained from a cell line infected with a bacteria.  
     
     
         5 . An immunogenic composition according to  claim 3  wherein the complex is obtained from cells infected with bacteria causing a disease selected from the group consisting of tuberculosis, gonorrhea, typhoid, meningitis, osteomyelitis, meningococcal septicemia, endometritis, conjunctivitis, peritonitis, pyelonephritis, pharyngitis, septic arthritis, cellulitis, epiglottitis, salpingitis, otitis media, shigella dysentery, and gastroenteritis.  
     
     
         6 . An immunogenic composition according to  claim 1  wherein the complex is obtained from virus-infected cells.  
     
     
         7 . An immunogenic composition according to  claim 6  wherein the complex is obtained from a cell line infected with a virus.  
     
     
         8 . An immunogenic composition according to  claim 1  wherein the complex is obtained from viral gene transfected cells.  
     
     
         9 . An immunogenic composition according to  claim 6  wherein the virus is selected from the group consisting of influenza, varicella, herpes simplex I, herpes simplex II, HIV-I, HIV-II, hepatitis A, hepatitis B, hepatitis C, adenovirus, measles and mumps.  
     
     
         10 . An immunogenic composition according to  claim 1  wherein the complex is obtained from tumor cells.  
     
     
         11 . An immunogenic composition according to  claim 10  wherein the complex is obtained from cells from tumor cell line.  
     
     
         12 . An immunogenic composition according to  claim 10  wherein the tumor cells are selected from the group consisting of adenocarcinomas, colon carcinoma, melanoma, breast carcinoma, leukemia, lymphoma, sarcoma, gastric carcinoma, glioblastoma, astrocytoma, bladder carcinoma, pleural mesothelioma, oat cell carcinoma, and bronchogenic carcinoma.  
     
     
         13 . An immunogenic composition according to  claim 10  wherein the tumor is induced by a chemical carcinogen.  
     
     
         14 . An immunogenic composition according to  claim 13  wherein the tumor is a hydrocarbon-induced tumor.  
     
     
         15 . An immunogenic composition according to  claim 14  wherein the tumor is a methylcholanthrene-induced tumor.  
     
     
         16 . A method of eliciting an immune response in a mammal comprising the steps of: 
 isolating a heat shock protein 70-peptide complex from the mammal from tumor cells or cells infected with a virus, bacteria or infectious agent; and    administering the heat shock protein peptide complex to the mammal in an amount effective to elicit an immune response.    
     
     
         17 . A method of eliciting an immune response according to  claim 16  wherein the heat shock protein 70-peptide complex is isolated from bacteria-infected cells.  
     
     
         18 . A method of eliciting an immune response. according to  claim 17  wherein the complex is obtained from cells infected with bacteria causing a disease selected from the group consisting of tuberculosis, gonorrhea, typhoid, meningitis, osteomyelitis, neningococcal septicemia, endometritis, conjunctivitis, peritonitis, pyelonephritis, pharyngitis, septic arthritis, cellulitis, epiglottitis, salpingitis, otitis media, shigella dysentery, and gastroenteritis.  
     
     
         19 . A method of eliciting an immune response according to  claim 16  wherein the heat shock protein 70-peptide complex is isolated from virus-infected cells.  
     
     
         20 . A method of eliciting an immune response according to  claim 19  wherein the virus is selected from the group consisting of influenza, varicella, herpes simplex I, herpes simplex II, HIV-I, HIV-II, hepatitis A, hepatitis B, hepatitis C, adenovirus, measles and mumps.  
     
     
         21 . A method of eliciting an immune response according to  claim 16  wherein the heat shock protein 70-peptide complex is isolated from tumor cells.  
     
     
         22 . A method of eliciting an immune response according to  claim 21  wherein the tumor cells are selected from the group consisting of adenocarcinomas, colon carcinoma, melanoma, breast carcinoma, leukemia, lymphoma, sarcoma, gastric carcinoma, glioblastoma, astrocytoma, bladder carcinoma, pleural mesothelioma, oat cell carcinoma, and bronchogenic carcinoma.  
     
     
         23 . A method of eliciting an immune response according to  claim 21  wherein the tumor is induced by a chemical carcinogen.  
     
     
         24 . A method eliciting an immune response according to  claim 23  wherein the complex is isolated from hydrocarbon-induced tumor cells.  
     
     
         25 . A method eliciting an immune response according to  claim 24  wherein the complex is isolated from methylcholanthrene-induced tumor cells.  
     
     
         26 . A method of preparing a heat shock protein 70-peptide complex capable of eliciting an immune response in a mammal comprising the steps of: 
 obtaining cells from a mammal wherein the cells are tumor cells or cells infected with a virus, bacteria or other infectious agent; and    harvesting a heat shock protein 70-peptide complex from the cells wherein the heat shock protein 70-peptide complex is prepared in the absence of ATP.    
     
     
         27 . A method according to  claim 26  wherein the cells are from a tumor cell line or cell line infected with a virus, bacteria or other infectious agent.  
     
     
         28 . A method according to  claim 26  wherein the cells are bacteria-infected cells.  
     
     
         29 . A method according to  claim 28  wherein the cells are from a cell line infected with a bacteria.  
     
     
         30 . A method according to  claim 28  wherein the cells are infected with a bacteria causing a disease selected from the group consisting of tuberculosis, gonorrhea, typhoid, meningitis, osteomyelitis, meningococcal septicemia, endometritis, conjunctivitis, peritonitis, pyelonephritis, pharyngitis, septic arthritis, cellulitis, epiglottitis, salpingitis, otitis media, shigella dysentery, and gastroenteritis.  
     
     
         31 . A method according to  claim 26  wherein the cells are virus-infected cells.  
     
     
         32 . A method according to  claim 31  wherein the cells are from a cell line infected with a virus.  
     
     
         33 . A method according to  claim 26  wherein the cells are viral gene transfected cells.  
     
     
         34 . A method according to  claim 31  wherein the virus is selected from the group consisting of influenza, varicella, herpes simplex I, herpes simplex II, HIV-I, HIV-II, hepatitis A, hepatitis B, hepatitis C, adenovirus, measles and mumps.  
     
     
         35 . A method according to  claim 26  wherein the cells are tumor cells.  
     
     
         36 . A method according to  claim 35  wherein the cells are from a tumor cell line.  
     
     
         37 . A method according to  claim 35  wherein the tumor cells are selected from the group consisting of adenocarcinomas, colon carcinoma, melanoma, breast carcinoma, leukemia, lymphoma, sarcoma, gastric carcinoma, glioblastoma, astrocytoma, bladder carcinoma, pleural mesothelioma, oat cell carcinoma, and bronchogenic carcinoma.  
     
     
         38 . A method according to  claim 35  wherein the tumor is induced by a chemical carcinogen.  
     
     
         39 . A method according to  claim 38  wherein the tumor is a hydrocarbon-induced tumor.  
     
     
         40 . A method according to  claim 39  wherein the tumor is a methylcholanthrene-induced tumor.  
     
     
         41 . A method of preparing an antigenic peptide composition comprising the steps of: 
 obtaining cells from a mammal wherein the cells are tumor cells or cells infected with a virus, bacteria or other infectious agent;    harvesting a heat shock protein 70-peptide complex from the cells wherein the heat shock protein 70-peptide complex is prepared in the absence of ATP; and    separating peptides from the heat shock protein 70-peptide complex, wherein the separated peptides are capable of eliciting an immune response in a mammal.    
     
     
         42 . A method of preparing an antigenic peptide composition according to  claim 41  wherein the cells are from a tumor cell line or a cell line infected with a virus, bacteria or other infectious agent.  
     
     
         43 . A method of preparing an antigenic peptide composition according to  claim 41  wherein the cells are bacteria-infected cells.  
     
     
         44 . A method of preparing an antigenic peptide composition according to  claim 43  wherein the cells are from a cell line infected with a bacteria.  
     
     
         45 . A method of preparing an antigenic peptide composition according to  claim 43  wherein the cells are infected with bacteria causing a disease selected from the group consisting of tuberculosis, gonorrhea, typhoid, meningitis, osteomyelitis, meningococcal septicemia, endometritis, conjunctivitis, peritonitis, pyelonephritis, pharyngitis, septic arthritis, cellulitis, epiglottitis, salpingitis, otitis media, shigella dysentery, and gastroenteritis.  
     
     
         46 . A method of preparing an antigenic peptide composition according to  claim 41  wherein the cells are virus-infected cells.  
     
     
         47 . A method of preparing an antigenic peptide composition according to  claim 46  wherein the cells are from a cell line infected with a virus.  
     
     
         48 . A method of preparing an antigenic peptide composition according to  claim 41  wherein the cells are viral gene transfected cells.  
     
     
         49 . A method of preparing an antigenic peptide composition according to  claim 46  wherein the virus is selected from the group consisting of influenza, varicella, herpes simplex I, herpes simplex II, HIV-I, HIV-II, hepatitis A, hepatitis B, hepatitis C, adenovirus, measles and mumps.  
     
     
         50 . A method of preparing an antigenic peptide composition according to  claim 41  wherein the cells are tumor cells.  
     
     
         51 . A method of preparing an antigenic peptide composition according to  claim 50  wherein the cells are from a tumor cell line.  
     
     
         52 . A method of preparing an antigenic peptide composition according to  claim 50  wherein the tumor cells are selected from the group consisting of adenocarcinomas, colon carcinoma, melanoma, breast carcinoma, leukemia, lymphoma, sarcoma, gastric carcinoma, glioblastoma, astrocytoma, bladder carcinoma, pleural mesothelioma, oat cell carcinoma, and bronchogenic carcinoma.  
     
     
         53 . A method of preparing an antigenic peptide composition according to  claim 50  wherein the tumor is induced by a chemical carcinogen.  
     
     
         54 . A method of preparing an antigenic peptide composition according to  claim 53  wherein the tumor is a hydrocarbon-induced tumor.  
     
     
         55 . A method of preparing an antigenic peptide composition according to  claim 54  wherein the tumor is a methylcholanthrene-induced tumor.